Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Doumas

Showing results (11-20 of 379) with videos related to

Pageof 38
Sort By:
Lancet (London, England)|April 1, 2009
Interventional management of resistant hypertensionMichael Doumas, Stella Douma
Journal of Clinical Hypertension (Greenwich, Conn.)|April 6, 2006
Sexual dysfunction in essential hypertension: myth or reality?Michael Doumas, Stella Douma
Expert Opinion on Pharmacotherapy|April 15, 2009
Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure controlVasilios Papademetriou, Michael Doumas
Current Hypertension Reports|May 15, 2012
Antihypertensive treatment and sexual dysfunctionAthanasios Manolis, Michael Doumas
Journal of Clinical Hypertension (Greenwich, Conn.)|May 12, 2006
The effect of antihypertensive drugs on erectile function: a proposed management algorithmMichael Doumas, Stella Douma
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 11, 2026
Hypertension in Diabetes: Numbers or Outcomes?Theocharis Koufakis, Michael Doumas
European Journal of Gastroenterology & Hepatology|February 4, 2020
Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitorsDimitrios Patoulias, Michael Doumas
Reumatologia|January 26, 2022
Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?Dimitrios Ioannis Patoulias, Michael Doumas
Angiology|May 21, 2021
A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 VaccineVasilios G Athyros, Michael Doumas
Current Vascular Pharmacology|March 31, 2018
Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and MortalityVasilios G Athyros, Michael Doumas
Pageof 38

Showing results (11-20 of 379) with videos related to

Sort By:
Pageof 38
Lancet (London, England)|April 1, 2009
Interventional management of resistant hypertensionMichael Doumas, Stella Douma
Journal of Clinical Hypertension (Greenwich, Conn.)|April 6, 2006
Sexual dysfunction in essential hypertension: myth or reality?Michael Doumas, Stella Douma
Expert Opinion on Pharmacotherapy|April 15, 2009
Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure controlVasilios Papademetriou, Michael Doumas
Current Hypertension Reports|May 15, 2012
Antihypertensive treatment and sexual dysfunctionAthanasios Manolis, Michael Doumas
Journal of Clinical Hypertension (Greenwich, Conn.)|May 12, 2006
The effect of antihypertensive drugs on erectile function: a proposed management algorithmMichael Doumas, Stella Douma
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 11, 2026
Hypertension in Diabetes: Numbers or Outcomes?Theocharis Koufakis, Michael Doumas
European Journal of Gastroenterology & Hepatology|February 4, 2020
Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitorsDimitrios Patoulias, Michael Doumas
Reumatologia|January 26, 2022
Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?Dimitrios Ioannis Patoulias, Michael Doumas
Angiology|May 21, 2021
A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 VaccineVasilios G Athyros, Michael Doumas
Current Vascular Pharmacology|March 31, 2018
Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and MortalityVasilios G Athyros, Michael Doumas
Pageof 38